TransCode Therapeutics, Inc. has announced on June 3, 2024, that it received a notification from the Nasdaq Office of General Counsel confirming the company's compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of regaining compliance, the scheduled Nasdaq Hearings Panel on June 25, 2024, has been cancelled. The company, however, will remain under the mandatory panel monitor until January 27, 2025, as per Nasdaq Listing Rule 5815(d)(4)(B). This development follows previous concerns regarding TransCode's adherence to Nasdaq's listing standards.

TransCode Therapeutics, Inc. has announced on June 3, 2024, that it received a notification from the Nasdaq Office of General Counsel confirming the company's compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of regaining compliance, the scheduled Nasdaq Hearings Panel on June 25, 2024, has been cancelled. The company, however, will remain under the mandatory panel monitor until January 27, 2025, as per Nasdaq Listing Rule 5815(d)(4)(B). This development follows previous concerns regarding TransCode's adherence to Nasdaq's listing standards.